Company / Shareholders' Equity
IRONWOOD PHARMACEUTICALS INC Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$261.8M
FY2025
5-year range
-$346.3M / $652.4M
FY2021-FY2025
Trend
+13.1%
vs FY2024
Sector context
#205 of 213
Health Care
What the data says
IRONWOOD PHARMACEUTICALS INC reports negative total equity of -$262M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$262M in FY2025.
Improved from -$346M to -$262M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 213This company -$261.8M Sector average $2.5B
▼
-110.3% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity increased 13.1% year-over-year.
- Ranks #205 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2022.
- Lowest shareholders' equity in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -2.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$261.8M | +13.1% |
| FY2024 | -$301.3M | +13.0% |
| FY2023 | -$346.3M | -153.1% |
| FY2022 | $652.4M | +7.7% |
| FY2021 | $605.9M | +408.6% |
| FY2020 | -$196.4M | -110.6% |
| FY2019 | -$93.3M | -239.8% |
| FY2018 | $66.7M | +577.5% |
| FY2017 | $9.8M | -85.2% |
| FY2016 | $66.7M | -29.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026